Top

Published in:

01-08-2010 | Review Article

International position paper on febuxostat

Authors: Tim L. Jansen, Pascal Richette, Fernando Perez-Ruiz, Anne-Kathrin Tausche, Philip-André Guerne, Leonardo Punzi, Burkhard Leeb, Victoria Barskova, Till Uhlig, José Pimentão, Irena Zimmermann-Górska, Elisio Pascual, Thomas Bardin, Michael Doherty

Published in: Clinical Rheumatology | Issue 8/2010

Excerpt

This position paper aims to clarify the presumed place of febuxostat in the management of gout patients. Since this novel xanthine oxidase inhibitor is now available as a new treatment option for patients with gout, an international group of gout experts decided to formulate a rheumatologic international consensus statement. This statement presents the place for this new xanthine oxidase inhibitor in the treatment of gout which may contribute to optimize treatment of gout patients in Europe and worldwide. …

Available only for authorised users

Wortmann RL (2005) Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 17:319–324CrossRefPubMed

Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65:1301–1311CrossRefPubMed

Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65:1312–1324CrossRefPubMed

Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G (2008) British society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 46:1372–1374CrossRef

Pascual E, Sivera F (2007) Why is gout so poorly managed? Ann Rheum Dis 66:1269–1270CrossRefPubMed

CHMP assessment report for Adenuric/febuxostat. Doc. ref. EMEA/258531/2008

Perez-Ruiz F (2009) Treating to target: a strategy to cure gout. Rheumatology 48:ii9–ii14CrossRefPubMed

Reinders MK, Van Roon EN, Jansen TLThA, Delsing J, Griep EN, Hoekstra M, Van de Laar MAFJ, Brouwers JRBJ (2009) Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68:51–56CrossRefPubMed

Reinders MK, Haagsma C, Jansen TLThA, Van Roon EN, Delsing J, Van de Laar MAFJ, Brouwers JRBJ (2009) A randomized controlled trial with dose escalation on the efficacy and tolerability of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in gout patients. Ann Rheum Dis 68:892–897CrossRefPubMed

10.

Becker MA, Schumacher HR, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461CrossRefPubMed

11.

Schumacher HR, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Care Res 59:1540–1548CrossRef

12.

Becker MA, Schumacher HR, Wortmann RL et al (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52:916–923CrossRefPubMed

13.

Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C (2009) Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 48:188–194CrossRefPubMed

Title: International position paper on febuxostat
Authors: Tim L. Jansen
Pascal Richette
Fernando Perez-Ruiz
Anne-Kathrin Tausche
Philip-André Guerne
Leonardo Punzi
Burkhard Leeb
Victoria Barskova
Till Uhlig
José Pimentão
Irena Zimmermann-Górska
Elisio Pascual
Thomas Bardin
Michael Doherty
Publication date: 01-08-2010
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 8/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1457-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2010

Is low-level laser therapy effective in acute or chronic low back pain?

Erratum to: Is low-level laser therapy effective in acute or chronic low back pain?

Leflunomide in the treatment of patients with early rheumatoid arthritis—results of a prospective non-interventional study

Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge

Additional effect of pulsed electromagnetic field therapy on knee osteoarthritis treatment: a randomized, placebo-controlled study

Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials